Media ReleasesImugene Limited

View All Imugene Limited News


US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy

Sydney, Australia, 23 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Professor, Department of Surgery and Director, Gastroenterology Minimally Invasive Therapy Program, together with Yuman Fong, MD, Professor and Chair of the Department of Surgery, received a $564,173 US Department of Defense Grant titled “Discovery of Immune Biomarkers That Predict Response to a Novel Chimeric Immuno-Oncolytic Virus Encoding Anti-PD-L1 in Gastric Cancer Peritoneal Carcinomatosis”. City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases based near Los Angeles.

For further information please download the attached PDF:
Download this document